AR088781A1 - Compuestos antimicrobianos y metodos para prepararlos y utilizarlos - Google Patents
Compuestos antimicrobianos y metodos para prepararlos y utilizarlosInfo
- Publication number
- AR088781A1 AR088781A1 ARP120101303A ARP120101303A AR088781A1 AR 088781 A1 AR088781 A1 AR 088781A1 AR P120101303 A ARP120101303 A AR P120101303A AR P120101303 A ARP120101303 A AR P120101303A AR 088781 A1 AR088781 A1 AR 088781A1
- Authority
- AR
- Argentina
- Prior art keywords
- unsaturated
- saturated
- group
- sulfur
- nitrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000000845 anti-microbial effect Effects 0.000 title 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 24
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 14
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 13
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 13
- 125000005842 heteroatom Chemical group 0.000 abstract 13
- 229910052757 nitrogen Inorganic materials 0.000 abstract 13
- 229910052760 oxygen Inorganic materials 0.000 abstract 13
- 239000001301 oxygen Chemical group 0.000 abstract 13
- 229910052717 sulfur Chemical group 0.000 abstract 13
- 239000011593 sulfur Chemical group 0.000 abstract 13
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 12
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 8
- 125000001424 substituent group Chemical group 0.000 abstract 8
- 125000000623 heterocyclic group Chemical group 0.000 abstract 7
- 125000002837 carbocyclic group Chemical group 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 125000004432 carbon atom Chemical group C* 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 150000001721 carbon Chemical group 0.000 abstract 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 3
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- -1 (i) -OCH3 Chemical class 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 101100006939 Zea mays CNR11 gene Proteins 0.000 abstract 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
- C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) o un tautómero del mismo, o una sal, éster o profármaco de dicho compuesto o tautómero farmacéuticamente aceptable, donde X¹ es CR¹ o N; X² es CR² o N; X³ es CR³ o N; X⁴ es CR⁴ o N; X⁵ es CR⁵ o N; con la condición de que X¹, X², X³, X⁴, y X⁵ no sean todos N; Y⁶ es CR⁶ o N; Y⁷, es CR⁷ o 6N; Y⁸ es CR⁸ o N; Y⁹ es CR⁹ o N; Y¹⁰ es CR¹⁰ o N; con la condición de que Y⁶, Y⁷, Y⁸, Y⁹, e Y¹⁰ no sean todos N; donde R¹, R², R⁴, R⁵, R⁶, R⁷, R⁸ y R¹⁰ se seleccionan, cada uno, independientemente de (a) hidrógeno, (b) F, (c) Cl, (d) Br, (e) I, (f) -CF₃, (g) -CF₂H, (h) -CFH₂, (i) -OCF₃, (j) -OCF₂H, (k) -OCFH₂, (l) -OCH₃, (m) -CN, (n) -N₃, (o) -NO₂, (p) -NR¹¹R¹¹, (q) -NR¹¹C(O)R¹¹, (r) -C(O)NR¹¹R¹¹, (s) -OR¹¹, (t) -COH, (u) -CO(alquilo C₁₋₈), (v) -COR¹¹, (w) -NR¹¹(CNR¹¹)NR¹¹R¹¹, (x) -S(O)ₚR¹¹, (y) -NR¹¹S(O)PR¹¹, (z) -SR¹¹, (aa) -SCF₃, (bb) -C(CF₃)H-NH-CHR¹¹R¹¹, (cc) -COOR¹¹, (dd) -(OCH₂CH₂)ₜR¹¹, (ee) -(OCH₂CH₂)ₜOR¹¹, (ff) -alquilo C₁₋₈, (gg) -alquenilo C₂₋₈, (hh) -alquinilo C₂₋₈, (ii) -(alquilo C₁₋₈)-(heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre), (jj) -(alquilo C₁₋₈)-(carbociclo saturado, insaturado o aromático de 3 - 14 miembros), (kk) -haloalquilo, (ll) -heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, (mm) -carbociclo saturado, insaturado o aromático de 3 - 14 miembros, y (nn) -CHR¹¹-NH-(heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre); donde cada (ff) hasta (nn) está opcionalmente sustituido con uno o más R¹²; alternativamente, donde dos sustituyentes seleccionados entre R⁶, R⁷, y R⁸ se toman junto con el átomo de carbono al que están ligados para formar (a) un carbocíclico saturado o insaturado de 3 - 7 miembros o (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre; donde cada (a) hasta (b) está opcionalmente sustituido con uno o más R¹²; cada R¹¹ se selecciona independientemente entre (a) hidrógeno, (b) halógeno, (c) -OH, (d) -SH, (e) -(alquilo C₁₋₈)OH, (f) -OCF₃, (g) -OCF₂H, (h) -OCFH₂, (i) -OCH₃, (j) -OR¹², (k) -COR¹², (l) -CN, (m) -NO₂, (n) -CONH₂, (o) -CONR¹²R¹², (p) -COCH₃, (q) -S(O)ₚCH₃, (r) -S(O)ₚNR¹²R¹², (s) -SR¹², (t) -C(O)OH, (u) -C(O)OR¹², (v) -N₃, (w) -NH₂, (x) -NR¹²C(O)R¹², (y) -NH(alquilo C₁₋₈), (z) -N(alquilo C₁₋₈)₂, (aa) -alquilo C₁₋₈, (bb) -alquenilo C₂₋₈, (cc) -alquinilo C₂₋₈, (dd) -haloalquilo, (ee) -(alquilo C₁₋₈)-(heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre), (ff) -(alquilo C₁₋₈)-(carbociclo saturado, insaturado o aromático de 3 - 14 miembros), (gg) -heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, (hh) -carbociclo saturado, insaturado o aromático de 3 - 14 miembros, y (ii) -(C=NH)NR¹²R¹²; donde cada (y) hasta (hh) está opcionalmente sustituido con uno o más R¹²; alternativamente dos sustituyentes R¹¹ se toman juntos para formar (a) un carbocíclico saturado o insaturado de 3 - 7 miembros o (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, donde cada (a) hasta (b) está opcionalmente sustituido con uno o más R¹²; R³ se selecciona entre el grupo de formulas (2), donde R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ, R³ᶠ, R³ᵍ, R³ʰ, R³ⁱ, R³ʲ, R³ᵏ, y R³ˡ se seleccionan, cada uno, independientemente de (a) hidrógeno, (b) halógeno, (c) -CN, (d) -N₃, (e) -NO₂, (f) -OCF₃, (g) -OCF₂H, (h) -OCFH₂, (i) -OCH₃, (j) -OR¹¹, (k) -C(O)R¹¹, (l) -C(O)NR¹¹R¹¹, (m) -NH₂, (n) -NR¹¹R¹¹, (o) -NR¹¹C(O)R¹¹, (p) -S(O)ₚR¹¹, (q) -C(O)OH, (r) -C(O)OR¹¹, (s) -alquilo C₁₋₈, (t) -alquenilo C₂₋₈, (u) -alquinilo C₂₋₈, (v) haloalquilo, (w) -heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, y (x) -carbociclo saturado, insaturado o aromático de 3 - 14 miembros; donde cada (s) hasta (x) está opcionalmente sustituido con uno o más R¹²; alternativamente, uno o más pares de sustituyentes seleccionados entre R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ y R³ᶠ, R³ᵍ y R³ʰ, R³ⁱ y R³ʲ, y R³ᵏ y R³ˡ se toman junto con el átomo de carbono al que están ligados para formar (a) un carbocíclico saturado o insaturados de 3 - 7 miembros, (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, (c) un enlace doble carbono-carbono exo, (d) un grupo carbonilo o (e) un grupo tiocarbonilo; donde cada (a) hasta (b) está opcionalmente sustituido con uno o más R¹²; alternativamente, donde dos sustituyentes seleccionados entre R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ, R³ᶠ, R³ᵍ, R³ʰ, R³ⁱ, R³ʲ, R³ᵏ, y R³ˡ en diferentes átomos de carbono se toman junto con los átomos que intervienen a los que están ligados para formar (a) un carbocíclico saturado o insaturado de 3 - 7 miembros o (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre; donde cada (a) hasta (b) está opcionalmente sustituido con uno o más R¹²; alternativamente, donde dos sustituyentes seleccionados entre R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ, R³ᶠ, R³ᵍ, R³ʰ, R³ⁱ, R³ʲ, R³ᵏ, y R³ˡ en dos átomos de carbono adyacentes se toman junto con el enlace entre dichos átomos de carbono adyacentes para formar un doble enlace carbono-carbono sustituido o insustituido, o donde cuatro sustituyentes seleccionados entre R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ, R³ᶠ, R³ᵍ, R³ʰ, R³ⁱ, R³ʲ, R³ᵏ, y R³ˡ en dos átomos de carbono adyacentes se toman junto con el enlace entre dichos átomos de carbono adyacentes para formar un enlace triple carbono-carbono; U se selecciona entre -O-, -S(O)ₚ-, -NR¹¹-, -(C=O)-, -NR¹¹(C=O)-, -(C=O)NR¹¹, -S(O)ₚNR¹¹-, -NR¹¹S(O)ₚ-, -NR¹¹S(O)ₚNR¹¹-, y -NR¹¹C(O)NR¹¹-; T se selecciona entre -NR¹¹R¹¹, -NR¹¹(C=O)OR¹¹, -NR¹¹(C=NR¹¹)NR¹¹R¹¹, y OR¹¹; alternativamente, un R¹¹ y un sustituyente seleccionado entre R³ᵃ, R³ᵇ, R³ᶜ, R³ᵈ, R³ᵉ, R³ᶠ, R³ᵍ, R³ʰ, R³ⁱ, R³ʲ, R³ᵏ, y R³ˡ se toman junto con los átomos que intervienen a los que están ligados para formar (a) un carbocíclico saturado o insaturado de 3 - 7 miembros o (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre; donde cada (a) hasta (b) está opcionalmente sustituido con uno o más R¹²; R⁹ se selecciona del grupo de formulas (3), donde R⁹ᵏ, R⁹ˡ, R⁹ᵐ, R⁹ⁿ, R⁹ᵒ, R⁹ᵖ, R⁹q, R⁹ʳ, R⁹ˢ, y R⁹ᵗ se seleccionan, cada uno, independientemente de (a) hidrógeno, (b) halógeno, (c) -CN, (d) -N₃, (e) -NO₂, (f) -OCF₃, (g) -OCH₃, (h) -OCF₂H, (i) -OCFH₂, (j) -OR¹¹, (k) -NH₂, (l) -NR¹¹R¹¹, (m) -C(O)R¹¹, (n) -C(O)OR¹¹, (o) -C(O)NR¹¹R¹¹, (p) -NR¹¹C(O)R¹¹, (q) -S(O)ₚR¹¹, (r) -alquilo C₁₋₈, (s) -alquenilo C₂₋₈, (t) -C₁₋₈ alquinilo, (u) haloalquilo, (v) -heterociclo saturado, insaturado o aromático de 3 - 14 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, y (w) -carbociclo saturado, insaturado o aromático de 3 - 14 miembros; donde cada (r) hasta (w) está opcionalmente sustituido con uno o más R¹²; alternativamente, uno o más pares de sustituyentes seleccionados entre R⁹ᵏ y R⁹ˡ, R⁹ᵐ y R⁹ⁿ, R⁹ᵒ y R⁹ᵖ, R⁹q y R⁹ʳ, R⁹ˢ y R⁹ᵗ se toman junto con el átomo de carbono al que están ligados para formar (a) un carbocíclico saturado o insaturado de 3 - 7 miembros, (b) un anillo heterocíclico saturado o insaturado de 3 - 7 miembros que contiene uno o más heteroátomos seleccionados del grupo formado por nitrógeno, oxígeno y azufre, (c) un enlace doble carbono-carbono exo, (d) un grupo carbonilo o (e) un grupo t
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476138P | 2011-04-15 | 2011-04-15 | |
| US201161535118P | 2011-09-15 | 2011-09-15 | |
| US201261610363P | 2012-03-13 | 2012-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088781A1 true AR088781A1 (es) | 2014-07-10 |
Family
ID=47357660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101303A AR088781A1 (es) | 2011-04-15 | 2012-04-16 | Compuestos antimicrobianos y metodos para prepararlos y utilizarlos |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9221827B2 (es) |
| EP (2) | EP2697229B1 (es) |
| JP (2) | JP6317669B2 (es) |
| KR (1) | KR20140065378A (es) |
| CN (2) | CN103958514B (es) |
| AR (1) | AR088781A1 (es) |
| AU (3) | AU2012271228B2 (es) |
| BR (1) | BR112013026410A2 (es) |
| CA (1) | CA2833169A1 (es) |
| DK (1) | DK2697229T3 (es) |
| EA (1) | EA201391536A1 (es) |
| ES (1) | ES2665988T3 (es) |
| HU (1) | HUE036755T2 (es) |
| IL (1) | IL228845A0 (es) |
| MX (1) | MX357903B (es) |
| MY (1) | MY173518A (es) |
| PH (1) | PH12013502135A1 (es) |
| PT (1) | PT2697229T (es) |
| SG (2) | SG10201603027QA (es) |
| TW (2) | TWI656123B (es) |
| WO (1) | WO2012173689A2 (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0739738Y2 (ja) | 1989-10-03 | 1995-09-13 | 三菱農機株式会社 | 機体転倒防止装置 |
| NZ599290A (en) | 2009-10-16 | 2014-10-31 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| EA201270568A1 (ru) | 2009-10-16 | 2012-11-30 | Риб-Экс Фармасьютикалз, Инк. | Антимикробные композиции и способы их получения и применения |
| NZ599291A (en) | 2009-10-16 | 2014-06-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| MY173518A (en) | 2011-04-15 | 2020-01-30 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| US9346802B2 (en) | 2013-03-15 | 2016-05-24 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
| EP2970266B1 (en) | 2013-03-15 | 2018-01-31 | Epizyme, Inc. | 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| AU2014227775B2 (en) | 2013-03-15 | 2018-05-31 | Epizyme, Inc. | CARM1 inhibitors and uses thereof |
| EP3038623A4 (en) * | 2013-09-09 | 2017-04-19 | Melinta Therapeutics, Inc. | Antimicrobial compounds and methods of making and using the same |
| SG10201801956SA (en) * | 2013-09-09 | 2018-04-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| US20180141897A1 (en) | 2014-12-08 | 2018-05-24 | The Research Foundation For The State University Of New York | Anti-fungals targeting the synthesis of fungal shingolipids |
| BR112017019349A2 (pt) * | 2015-03-11 | 2018-06-05 | Melinta Therapeutics Inc | compostos antimicrobianos e métodos de fabricação e uso dos mesmos |
| CN105669519B (zh) * | 2016-01-04 | 2018-01-05 | 北方民族大学 | 吲哚类化合物、制备方法及其作为抗耐药菌药物的应用 |
| US11098047B2 (en) * | 2016-05-06 | 2021-08-24 | BioVersys AG | Antimicrobials and methods of making and using same |
| MX2018013545A (es) | 2016-05-06 | 2019-08-14 | Melinta Therapeutics Inc | Antimicrobianos y metodos de preparacion y uso de los mismos. |
| WO2017193023A1 (en) * | 2016-05-06 | 2017-11-09 | Melinta Therapeutics, Inc. | Antimicrobials and methods of making and using same |
| WO2018232298A1 (en) | 2017-06-16 | 2018-12-20 | The Research Foundation For The State University Of New York | Anti-fungals compounds targeting the synthesis of fungal sphingolipids |
| TW201904970A (zh) | 2017-06-19 | 2019-02-01 | 美商梅林塔療法公司 | 抗微生物劑及製造及使用方法 |
| US20210403473A1 (en) * | 2018-02-21 | 2021-12-30 | BioVersys AG | Antimicrobial compounds and methods of making and using the same |
| WO2019234509A2 (en) | 2018-06-06 | 2019-12-12 | BioVersys AG | Aminomethylamidine and methylamidine antimicrobial compounds |
| WO2019234508A1 (en) | 2018-06-06 | 2019-12-12 | BioVersys AG | Biodefense agents |
| WO2020115547A2 (en) * | 2018-12-07 | 2020-06-11 | BioVersys AG | Pyrrolo[2,3-d]pyrimidin-2-one antimicrobial compounds |
| EP4058146B1 (en) * | 2019-11-13 | 2024-10-23 | Curza Global LLC | Antimicrobial compounds and methods |
| CN111254091B (zh) * | 2020-01-20 | 2022-04-19 | 浙江工业大学 | 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| JP2873340B2 (ja) | 1988-04-29 | 1999-03-24 | 武田薬品工業株式会社 | 抗生物質ｔａｎ―１０５７，その製造法および用途 |
| US5958930A (en) | 1991-04-08 | 1999-09-28 | Duquesne University Of The Holy Ghost | Pyrrolo pyrimidine and furo pyrimidine derivatives |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| GB9708611D0 (en) | 1997-04-28 | 1997-06-18 | Univ Cardiff | Chemical compounds |
| US6110925A (en) | 1997-08-07 | 2000-08-29 | Research Corporation Technologies, Inc. | Antibiotic for methicillin resistant bacteria |
| DE19838998A1 (de) | 1998-08-27 | 2000-03-09 | Bayer Ag | Neue Naturstoffderivate |
| EP1113008A1 (en) | 1999-12-29 | 2001-07-04 | Pfizer Products Inc. | 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents |
| KR100358083B1 (ko) * | 2000-02-17 | 2002-10-25 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도 |
| DE10061537A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | beta-Alanin-Derivate |
| DE10061542A1 (de) | 2000-12-11 | 2002-06-13 | Bayer Ag | Alkanoylamino-pyrimidine |
| DE10061541A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Arylamino-Dihydropyrimidinone |
| DE10061538A1 (de) | 2000-12-11 | 2002-06-20 | Bayer Ag | Ureido-Dihydropyrimidinone |
| US6900215B2 (en) | 2000-12-15 | 2005-05-31 | Merck Sharp & Dohme Ltd. | Imidazo-pyrimidine derivatives as ligands for gaba receptors |
| DE10133277A1 (de) | 2001-07-09 | 2003-01-23 | Bayer Ag | ß-Alanin-Derivate |
| DE10141271A1 (de) | 2001-08-23 | 2003-03-06 | Bayer Ag | Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung |
| DE10208256A1 (de) | 2002-02-26 | 2003-09-04 | Bayer Ag | Piperidinouracile |
| WO2004080466A1 (en) | 2003-03-07 | 2004-09-23 | Ribapharm Inc. | Cytidine analogs and methods of use |
| TW200519116A (en) * | 2003-08-26 | 2005-06-16 | Teijin Pharma Ltd | Pyrrolopyrimidine derivatives |
| NZ544187A (en) | 2005-12-15 | 2008-07-31 | Ind Res Ltd | Deazapurine analogs of 1'-aza-l-nucleosides |
| MX2009000102A (es) * | 2006-07-03 | 2009-03-02 | Sk Chemicals Co Ltd | Sales de derivados de pirrolopirimidinona y proceso para prepararlas. |
| KR20080003599A (ko) * | 2006-07-03 | 2008-01-08 | 에스케이케미칼주식회사 | 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법 |
| US20100112561A1 (en) | 2006-08-25 | 2010-05-06 | Stefan Lutz | Fluorescent nucleoside analogues |
| HRP20110408T1 (hr) | 2006-09-07 | 2011-06-30 | Industrial Research Limited | Inhibitori nukleozidnih fosforilaza i hidrolaza acikličkog amina |
| JP2008222557A (ja) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | ピロロ［３，２−ｄ］ピリミジン誘導体及びこれを有効成分とする医薬組成物 |
| CA2691987C (en) | 2007-06-12 | 2016-08-16 | Achaogen, Inc. | Antibacterial agents |
| GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
| KR20090098710A (ko) | 2008-03-14 | 2009-09-17 | 주식회사 씨티아이바이오 | 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체 |
| UY32395A (es) | 2009-01-27 | 2010-08-31 | Takeda Pharmaceutical | Compuesto con anillo fusionado y su uso |
| EP3424939A1 (en) * | 2009-03-02 | 2019-01-09 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
| ES2620177T3 (es) | 2009-10-15 | 2017-06-27 | Guerbet | Agentes de formación de imágenes y su uso para el diagnóstico in vivo de enfermedades neurodegenerativas, particularmente la enfermedad de Alzheimer y enfermedades derivadas |
| CN104628729B (zh) * | 2009-10-16 | 2018-11-06 | 梅琳塔治疗公司 | 抗微生物化合物和其制备和使用方法 |
| NZ599291A (en) | 2009-10-16 | 2014-06-27 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
| MY173518A (en) | 2011-04-15 | 2020-01-30 | Melinta Therapeutics Inc | Antimicrobial compounds and methods of making and using the same |
-
2012
- 2012-04-11 MY MYPI2013003732A patent/MY173518A/en unknown
- 2012-04-11 EA EA201391536A patent/EA201391536A1/ru unknown
- 2012-04-11 WO PCT/US2012/032994 patent/WO2012173689A2/en not_active Ceased
- 2012-04-11 ES ES12799934.0T patent/ES2665988T3/es active Active
- 2012-04-11 MX MX2013012015A patent/MX357903B/es active IP Right Grant
- 2012-04-11 EP EP12799934.0A patent/EP2697229B1/en active Active
- 2012-04-11 HU HUE12799934A patent/HUE036755T2/hu unknown
- 2012-04-11 SG SG10201603027QA patent/SG10201603027QA/en unknown
- 2012-04-11 PH PH1/2013/502135A patent/PH12013502135A1/en unknown
- 2012-04-11 CN CN201280029215.5A patent/CN103958514B/zh not_active Expired - Fee Related
- 2012-04-11 CA CA2833169A patent/CA2833169A1/en not_active Abandoned
- 2012-04-11 SG SG2013076575A patent/SG194489A1/en unknown
- 2012-04-11 AU AU2012271228A patent/AU2012271228B2/en not_active Ceased
- 2012-04-11 EP EP18162332.3A patent/EP3404028A1/en not_active Withdrawn
- 2012-04-11 KR KR1020137030273A patent/KR20140065378A/ko not_active Ceased
- 2012-04-11 JP JP2014505231A patent/JP6317669B2/ja active Active
- 2012-04-11 US US14/112,027 patent/US9221827B2/en active Active
- 2012-04-11 BR BR112013026410A patent/BR112013026410A2/pt not_active Application Discontinuation
- 2012-04-11 PT PT127999340T patent/PT2697229T/pt unknown
- 2012-04-11 DK DK12799934.0T patent/DK2697229T3/en active
- 2012-04-11 CN CN201810630324.1A patent/CN109053695A/zh active Pending
- 2012-04-13 TW TW101113195A patent/TWI656123B/zh not_active IP Right Cessation
- 2012-04-13 TW TW107106234A patent/TW201843154A/zh unknown
- 2012-04-16 AR ARP120101303A patent/AR088781A1/es unknown
-
2013
- 2013-10-13 IL IL228845A patent/IL228845A0/en unknown
-
2015
- 2015-11-04 US US14/932,508 patent/US20190322668A1/en not_active Abandoned
-
2017
- 2017-07-12 AU AU2017204803A patent/AU2017204803A1/en not_active Abandoned
-
2018
- 2018-03-30 JP JP2018068456A patent/JP2018115206A/ja active Pending
-
2019
- 2019-07-02 AU AU2019204745A patent/AU2019204745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR088781A1 (es) | Compuestos antimicrobianos y metodos para prepararlos y utilizarlos | |
| AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
| AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
| AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
| AR091981A1 (es) | Dihidropiridona p1 como inhibidores del factor xia | |
| AR091023A1 (es) | Inhibidores del nampt | |
| AR093504A1 (es) | 4-(orto)-fluorofenil-5-fluoropirimidin-2-ilaminas que contienen un grupo sulfoximina como inhibidores de cdk9, un intermediario para su sintesis y metodos de obtencion de ambos compuestos | |
| AR094313A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR093505A1 (es) | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina que contienen un grupo sulfoximina | |
| AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| AR094557A1 (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
| AR090220A1 (es) | Inhibidores de serina/treonina cinasa | |
| AR093308A1 (es) | Derivados triciclicos fusionados de tiofeno como inhibidores de jak | |
| AR095326A1 (es) | Heterociclos tricíclicos como inhibidores de la proteína bet | |
| AR107354A1 (es) | Salicilamidas espiroheptanos y compuestos relacionados como inhibidores de rock | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR088097A1 (es) | Compuestos herbicidas | |
| AR107042A1 (es) | Inhibidores de la tirosina quinasa de bruton y métodos de su uso | |
| AR091022A1 (es) | Inhibidores del nampt | |
| AR096613A1 (es) | Moduladores de la acetil-coa carboxilasa | |
| AR101528A1 (es) | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina | |
| AR115906A1 (es) | Derivados de haloalilamina sulfona como inhibidores de lisil oxidasas | |
| AR093503A1 (es) | Derivados de n-(piridin-2-il)pirimidin-4-amina que contienen un grupo sulfoximina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |